Results 1 to 10 of about 23,326 (221)
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis [PDF]
New England Journal of Medicine, 2016 BACKGROUND Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important drivers of atopic or allergic diseases such as atopic dermatitis ...
Thomas Bieber +2 more
exaly +3 more sources
Dupilumab for bullous pemphigoid with intractable pruritus [PDF]
, 2019 Bullous pemphigoid (BP) is an autoimmune blistering disorder that predominantly affects the elderly. Treatment regimens typically include topical and systemic immunosuppressive medications.
Jason S. Seidman +2 more
openalex +3 more sources
Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis [PDF]
American Journal of Clinical Dermatology, 2019 Background: Patients with moderate-to-severe atopic dermatitis (AD) have increased infection risk, including skin infections and systemic infections. Immunomodulators (e.g., anti-tumor necrosis factors, anti-interleukin [anti-IL]-23, anti-IL-17, Janus ...
Lawrence Eichenfield +2 more
exaly +3 more sources
Reactions Weekly, 2020 Ein neues Biologikum, das zur systemischen Behandlung der atopischen Dermatitis eingesetzt werden kann. Dupilumab ist bisher nicht direkt mit anderen systemischen Therapien verglichen worden und verursacht sehr häufig Augensymptome ...
+7 more sources
Short communication: Comments on hair disorders associated with dupilumab based on VigiBase.
PLoS ONE, 2022 BackgroundDupilumab is a human antibody that blocks the signaling of both interleukin-4 and interleukin-13 receptors. It has been approved for the treatment of moderate-to-severe atopic dermatitis.
Sunny Park +3 more
doaj +2 more sources
Clinical and Translational Allergy, 2023 Background The patho‐mechanism of ocular surface disease (OSD) in dupilumab‐treated atopic dermatitis (AD) patients remains unclear. The aim of this study is to measure dupilumab levels in tear fluid and serum, and relate these findings to the severity ...
Roselie Achten +13 more
doaj +1 more source
Uveitis and hypereosinophilia associated with dupilumab in an atopic dermatitis patient
Journal of Dermatological Treatment, 2023 Uveitis is a rare adverse event of dupilumab, that typically affects both eyes and often leads to discontinuation of therapy. In this article, we report a case of a 28-year-old female with atopic dermatitis who developed new-onset iridocyclitis, a form ...
Shiyu Zhang +8 more
doaj +1 more source
Dupilumab-associated cicatrizing ocular disease
American Journal of Ophthalmology Case Reports, 2022 Purpose: To describe three cases of bilateral cicatrizing conjunctivitis associated with dupilumab treatment for atopic dermatitis. Observations: Case 1 is a 69 year-old male with a history of mild, stable cicatrizing conjunctivitis thought to be ...
Amit K. Reddy +4 more
doaj +1 more source
BMC Pulmonary Medicine, 2022 Background Dupilumab, an anti-IL-4α receptor antibody, is a new treatment for severe or refractory asthma. However, real-world evidence on the efficacy of dupilumab in patients with mild to moderate bronchial asthma is lacking. Methods We retrospectively
Shunsuke Minagawa +8 more
doaj +1 more source
Virus-Like Particle-Mediated Vaccination against Interleukin-13 May Harbour General Anti-Allergic Potential beyond Atopic Dermatitis [PDF]
, 2020 Virus-like particle (VLP)-based anti-infective prophylactic vaccination has been established in clinical use. Although validated in proof-of-concept clinical trials in humans, no VLP-based therapeutic vaccination against self-proteins to modulate chronic
Foerster, John, Molęda, Aleksandra
core +2 more sources